J3 Bioscience Overview
- Founded
- 2007
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Later Stage VC
- Latest Deal Amount
- $20K
- Investors
- 2
J3 Bioscience General Information
Description
Developer of a biomedical device designed to help improve female reproductive health. The company's device is a Lubricating Intravaginal Ring (IVR) that continuously delivers moisture and contains no hormones or drugs and is also long-lasting, enabling women to maintain vaginal health.
Contact Information
Website
www.j3bio.com
Formerly Known As
Viropan
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Primary Office
- Northgate Park, 825 North 300 West
- Suite N231
- Salt Lake City, UT 84103
- United States
+1 (801) 000-0000
J3 Bioscience Timeline
J3 Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC | 04-Mar-2022 | $20K | 00.000 | Completed | Generating Revenue | |
| 6. Later Stage VC (Series A3) | 11-May-2021 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
| 5. Later Stage VC (Series A2) | 18-Dec-2019 | 00000 | 00.000 | 0000 | Completed | Generating Revenue |
| 4. Later Stage VC (Series A1) | 28-Aug-2017 | 00000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 3. Seed Round | 23-Nov-2015 | 00.000 | 00.000 | 00.000 | Completed | Generating Revenue |
| 2. Seed Round | 29-Nov-2012 | $540K | $1.24M | 00.000 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 18-Jul-2007 | $700K | $700K | 00.00 | Completed | Generating Revenue |
J3 Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A-3 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A-1 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00 | 00.0 | 0.000 | |
| Seed II | 1,400,000 | $0.010000 | $0.6 | $0.6 | 1x | $0.6 | 9.88% | |
| Seed I | 4,400,000 | $0.010000 | $0.3 | $0.3 | 1x | $0.3 | 31.04% |
J3 Bioscience Executive Team (4)
J3 Bioscience Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Duck Lee Ph.D | J3 Bioscience | Co-Chief Executive Officer, Green Cross Cell Clinical Development & Board Member | 000 0000 |
| Jayne Carney Ph.D | J3 Bioscience | Executive of Market/Commercial, M&A, Licensing & Board Member | 000 0000 |
| Larry Rigby | Self | Board Member & Global Market Advisor | 000 0000 |
| Ron Nielsen | J3 Bioscience | Board Member | 000 0000 |
| R. Tyler McCabe Ph.D | J3 Bioscience | Co-Chief Executive Officer, Development Lead & Board Member | 000 0000 |
J3 Bioscience Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialJ3 Bioscience Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Salt Lake Life Science Angels | Angel Group | Minority | 000 0000 | 000000 0 | |
| Tech Coast Angels | Angel Group | Minority | 000 0000 | 000000 0 |